TWST · Twist Bioscience Corp
$136.40
-6.00 (-4.21%)
At close · Aug 20
Market Cap
$8.55B
Shares
62.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$142.39
Open$128.00
Day$127.75–142.84
52W close$24.16–142.39
Avg vol 30d1.5M
Short int14.1M · 22.4% float · 11.1d
Short vol46%
Last earningsAug 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 11 wks
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+145%
above
Price vs 50-day avg
+47%
above
RSI (14)
71
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+51%
trailing
6-month return
+192%
trailing
YTD return
+349%
this year
Relative strength
+181%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $97 › 200d $58 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +91 funds added
Insider flow
Distributing
Net -$4.3M over 90 days · 100% sells
Short interest
Falling
22.45% of float · ▼ -0.3% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
336 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+64%
Y/Y
Free cash flow
$-75.6M
Balance sheet
$181.6M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
full fiscal year 2026
Total revenue
Raised
$456M – $457M
Nov 14, 2025
$425M – $435M
changed to
Aug 3, 2026
$456M – $457M
prior FY $376.57M
midpoint +21.2% Y/Y
Gross margin
at least 52%
fourth quarter of fiscal 2026
Total revenue
Initiated
$123M – $124M
prior qtr $118.38M
midpoint +4.3% QoQ
Prior guidance
period ended
· from the 8-K filed May 4, 2026
Total revenue
· third quarter
$114M – $115M
Guided vs delivered
· last 3 settled
Total revenue
fiscal 2024
guided $288M – $293M
$312.97M
Beat +7.7%
Overall revenue
second quarter of fiscal 2024
guided $70M – $71M
$75.3M
Beat +6.8%
Revenue
fourth quarter of fiscal '24
guided $78M
$84.71M
Beat +8.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+145%
Bullish
Price vs 50-day avg
+47%
Bullish
RSI (14)
71
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $97 › 200d $58 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +91 funds added
Insider flow
Distributing
Net -$4.3M over 90 days · 100% sells
Short interest
Falling
22.45% of float · ▼ -0.3% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
336 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24
Now $142 · 100%
Range high $142
vs 200-day avg +145%
vs 50-day avg +47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$11.3M | third quarter of fiscal 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP EBITDA -$29.46M
+$0K Litigation settlement costs, net of recoveries
+$0K Gain on sale of business
-$40K Other (income) expense, net
+$18.18M Stock-based compensation expense
= Adjusted EBITDA -$11.33M
|
|||
| Cash, cash equivalents and short-term investments | $167M | As of June 30, 2026 | — |
| Customers shipped to | 2,650 | third quarter of fiscal 2026 | — |
|
|
|||
| Genes physically shipped | 369,000 | third quarter of fiscal 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TWST
this stock
Twist Bioscience Corp
|
$8.55B | +348.9% | +20.3% | — | 22.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$231.21B | +5.9% | +14.5% | 33.6 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$46.86B | +41.9% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -16.9% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TWST | +13.7% | +51.1% | +192.3% | +55.5% | +348.9% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +14.2% | +48.2% | +180.8% | +52.6% | +336.1% |
Key facts
CIK
1581280
CUSIP
90184D100
13F (30d)
346 filings
313 filers
Visit website
Investor relations